These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9806652)

  • 1. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy.
    Shah M; Jenis EH; Mookerjee BK; Schriber JR; Baer MR; Herzig GP; Wetzler M
    Cancer; 1998 Nov; 83(9):1938-46. PubMed ID: 9806652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature.
    Bremer CT; Lastrapes A; Alper AB; Mudad R
    Am J Clin Oncol; 2003 Jun; 26(3):262-4. PubMed ID: 12796597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
    Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Anstrom KJ; Reed SD; Allen AS; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2584-92. PubMed ID: 15493041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myeloid leukaemia.
    Galesic K; Bozic B; Racic I; Scukanec-Spoljar M
    Nephrology (Carlton); 2006 Feb; 11(1):49-52. PubMed ID: 16509932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
    Deininger M; Pönisch W; Krahl R; Leiblein S; Edel E; Lange T; Fiedler F; Freund M; Franke A; Pasold R; von Grünhagen U; Herold M; Dölken G; Hoffmann FA; Uhle R; Schultze W; Steglich J; Schwarzer A; Richter P; Winkelmann C; Kettner E; Dachselt K; Subert R; Schwalbe E; Doepper J; Helbig W; Niederwieser D;
    Bone Marrow Transplant; 2001 Jun; 27(11):1125-32. PubMed ID: 11551022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic myelogenous leukemia].
    Ohnishi K
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1199-205. PubMed ID: 11579630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mini-ICE regimen allows mobilization of peripheral blood progenitor cells in a patient with chronic myelogenous leukemia failing the ICE protocol.
    Salar A; Sureda A; Menéndez B; Sierra J
    Haematologica; 2000 Mar; 85(3):326-7. PubMed ID: 10702830
    [No Abstract]   [Full Text] [Related]  

  • 12. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?
    Ravandi-Kashani F; Cortes J; Talpaz M; Kantarjian HM
    Cancer; 1999 Jun; 85(12):2583-8. PubMed ID: 10375106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
    Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests.
    Janssen JJ; van Rijn RS; van der Holt B; Schuurhuis GJ; Vellenga E; Verhoef GE; Ossenkoppele GJ; van den Berg E; Hagemeijer A; Släter R; Nieuwint AW; Cornelissen JJ
    Bone Marrow Transplant; 2000 Jun; 25(11):1147-55. PubMed ID: 10849527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
    Cervantes F; Sureda A; Hernández-Boluda JC; Martino R; Brunet S; Borrego D; Antich JL; Montserrat E
    Haematologica; 2001 Dec; 86(12):1281-6. PubMed ID: 11726320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
    Tóthová E; Fricová M; Stecová N; Kafková A; Mudronová B; Svorcová E; Guman T; Raffac S; Hlebasková M
    Cas Lek Cesk; 2000 Jul; 139(14):437-9. PubMed ID: 11048406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon.
    McBride NC; Cavenagh JD; Newland AC; Lillington DM; Murrell C; Kelsey SM
    Bone Marrow Transplant; 2000 Dec; 26(11):1165-72. PubMed ID: 11149726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase.
    Russo D; Marin L; Bertone A; Tiribelli M; Testoni N; Martinelli G
    Haematologica; 1999 Feb; 84(2):185-7. PubMed ID: 10091422
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
    Peñarrubia MJ; Odriozola J; González C; Massagué I; Miguel A; González San Miguel JD; Pérez Encinas M; Lavilla E; Giraldo MP; Casado LF; Ferrer S; Steegmann JL;
    Ann Hematol; 2003 Dec; 82(12):750-8. PubMed ID: 14517691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].
    Tóthová E; Stecová N; Kafková A; Fricová M; Svorcová E
    Vnitr Lek; 2002 May; 48(5):380-3. PubMed ID: 12061203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.